Prevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compound

BACKGROUND: The use of neurotrophic factors to treat Alzheimer’s disease (AD) is hindered by their blood–brain barrier impermeability, short half-life, and severe side effects. Peptide 021 (P021) is a neurotrophic/neurogenic tetra-peptide that was derived from the most active region of the ciliary n...

Descripción completa

Detalles Bibliográficos
Autores principales: Baazaoui, Narjes, Iqbal, Khalid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5488423/
https://www.ncbi.nlm.nih.gov/pubmed/28655344
http://dx.doi.org/10.1186/s13195-017-0273-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5488423/
https://www.ncbi.nlm.nih.gov/pubmed/28655344
http://dx.doi.org/10.1186/s13195-017-0273-7

Ejemplares similares